Skip to content
2000
image of The Safety and Efficacy of Anti-LAG-3 for Patients with Melanoma: A Systematic Review and Meta-analysis Study

Abstract

Introduction

Melanoma, an aggressive skin cancer, has seen treatment advancements with immune checkpoint inhibitors (ICIs) like ipilimumab and nivolumab. Despite improved survival rates, resistance remains a challenge. The recent focus on lymphocyte activation gene-3 (LAG-3) inhibitors, such as relatlimab, shows promise in combination therapies, potentially improving outcomes with fewer adverse effects. This review evaluates the safety and efficacy of anti-LAG-3 antibodies in melanoma treatment.

Methods

This systematic review and meta-analysis, following the PRISMA guidelines and registered in PROSPERO (CRD42024565756), assessed anti-LAG-3 antibodies in melanoma treatment. A thorough search across PubMed, Embase, Scopus, and Web of Science up to January 2024 yielded relevant studies. Data on study characteristics, patient demographics, disease characteristics, treatment details, and clinical outcomes were extracted. Quality assessment was performed using the MINOR criteria. The meta-analysis, using STATA and random-effects models, addressed heterogeneity to determine safety and efficacy outcomes.

Results

We examined the clinical benefit of this combination therapeutic approach by measuring several primary endpoints and running a meta-analysis to determine the pooled estimate of 6-month progression-free survival (PFS), 1-year PFS, 6-month duration of response (DoR), 1-year DoR, 1-year overall survival (OS), 2-year OS, partial response (PR), complete response (CR), objective response rate (ORR), disease control rate (DCR), stable disease (SD), and progressive disease (PD) for patients diagnosed with melanoma. Our analysis showed 66% of any grade treatment-related adverse events (trAEs) (95% CI: 51%-81%), 19% of grade ≥ 3 trAEs (95% CI: 11%-27%), 12% of any grade AEs leading to discontinuation (95% CI: 9%-14%), and 8% of grade ≥ 3 AEs leading to discontinuation (95% CI: 6%-10%). 76% of any grade overall AEs (95% CI: 34%-100%), and 33% of grade ≥ 3 overall AEs (95% CI: 15%-50%). The most common AEs were fatigue, pneumonitis, rash, pruritus, colitis, hepatitis, diarrhea, hypothyroidism, thyroiditis, and adrenal insufficiency.

Discussion

This systematic review and meta-analysis provide comprehensive evidence regarding the safety and efficacy of anti-LAG-3 antibodies in melanoma therapy. Pooled data reveals encouraging outcomes across several key endpoints, including PFS, OS, and ORR. While trAEs were common (66% for any grade and 19% for grade ≥3), most were manageable.

Conclusion

Anti-LAG-3 therapy is an active and safe treatment that shows promising results in melanoma treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206375121250701073343
2025-07-11
2025-09-14

  • From This Site

    /content/journals/acamc/10.2174/0118715206375121250701073343
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Hamid O. Robert C. Daud A. Hodi F.S. Hwu W.J. Kefford R. Wolchok J.D. Hersey P. Joseph R.W. Weber J.S. Dronca R. Gangadhar T.C. Patnaik A. Zarour H. Joshua A.M. Gergich K. Elassaiss-Schaap J. Algazi A. Mateus C. Boasberg P. Tumeh P.C. Chmielowski B. Ebbinghaus S.W. Li X.N. Kang S.P. Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013 369 2 134 144 10.1056/NEJMoa1305133 23724846
    [Google Scholar]
  2. Larkin J. Chiarion-Sileni V. Gonzalez R. Grob J.J. Cowey C.L. Lao C.D. Schadendorf D. Dummer R. Smylie M. Rutkowski P. Ferrucci P.F. Hill A. Wagstaff J. Carlino M.S. Haanen J.B. Maio M. Marquez-Rodas I. McArthur G.A. Ascierto P.A. Long G.V. Callahan M.K. Postow M.A. Grossmann K. Sznol M. Dreno B. Bastholt L. Yang A. Rollin L.M. Horak C. Hodi F.S. Wolchok J.D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015 373 1 23 34 10.1056/NEJMoa1504030 26027431
    [Google Scholar]
  3. Andrews L.P. Marciscano A.E. Drake C.G. Vignali D.A.A. LAG 3 (CD 223) as a cancer immunotherapy target. Immunol. Rev. 2017 276 1 80 96 10.1111/imr.12519 28258692
    [Google Scholar]
  4. Ascierto P.A. Melero I. Bhatia S. Sanbor R.E. Melero I. Bono P. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3: BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J. Clin. Oncol. 2017 35 9520 9520 10.1200/JCO.2017.35.15_suppl.9520
    [Google Scholar]
  5. Kooshkaki O. Derakhshani A. Hosseinkhani N. Torabi M. Safaei S. Brunetti O. Racanelli V. Silvestris N. Baradaran B. Combination of ipilimumab and nivolumab in cancers: From clinical practice to ongoing clinical trials. Int. J. Mol. Sci. 2020 21 12 4427 10.3390/ijms21124427 32580338
    [Google Scholar]
  6. Tawbi H.A. Schadendorf D. Lipson E.J. Ascierto P.A. Matamala L. Castillo Gutiérrez E. Rutkowski P. Gogas H.J. Lao C.D. De Menezes J.J. Dalle S. Arance A. Grob J.J. Srivastava S. Abaskharoun M. Hamilton M. Keidel S. Simonsen K.L. Sobiesk A.M. Li B. Hodi F.S. Long G.V. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 2022 386 1 24 34 10.1056/NEJMoa2109970 34986285
    [Google Scholar]
  7. Lipson E.J. Hassan A.M. Schadendorf D. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047. J. Clin. Oncol. 2021 ••• 9503 9503 10.1200/JCO.2021.39.15_suppl.9503
    [Google Scholar]
  8. Stultz J. Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021 24 3 697 717 10.1038/s41391‑021‑00340‑5 33820953
    [Google Scholar]
  9. Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. Shamseer L. Tetzlaff J.M. Akl E.A. Brennan S.E. Chou R. Glanville J. Grimshaw J.M. Hróbjartsson A. Lalu M.M. Li T. Loder E.W. Mayo-Wilson E. McDonald S. McGuinness L.A. Stewart L.A. Thomas J. Tricco A.C. Welch V.A. Whiting P. Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021 372 71 10.1136/bmj.n71 33782057
    [Google Scholar]
  10. Slim K. Nini E. Forestier D. Kwiatkowski F. Panis Y. Chipponi J. Methodological index for non randomized studies (MINORS): development and validation of a new instrument. ANZ J. Surg. 2003 73 9 712 716 10.1046/j.1445‑2197.2003.02748.x 12956787
    [Google Scholar]
  11. Amaria R.N. Postow M. Burton E.M. Tetzlaff M.T. Ross M.I. Torres-Cabala C. Glitza I.C. Duan F. Milton D.R. Busam K. Simpson L. McQuade J.L. Wong M.K. Gershenwald J.E. Lee J.E. Goepfert R.P. Keung E.Z. Fisher S.B. Betof-Warner A. Shoushtari A.N. Callahan M. Coit D. Bartlett E.K. Bello D. Momtaz P. Nicholas C. Gu A. Zhang X. Korivi B.R. Patnana M. Patel S.P. Diab A. Lucci A. Prieto V.G. Davies M.A. Allison J.P. Sharma P. Wargo J.A. Ariyan C. Tawbi H.A. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 2022 611 7934 155 160 10.1038/s41586‑022‑05368‑8 36289334
    [Google Scholar]
  12. Karapetyan L. Karapetyan L. Karapetyan L. Karapetyan L. Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy. J. Clin. Oncol. 2022 40 9514 9514
    [Google Scholar]
  13. Ascierto P.A. Lipson E.J. Dummer R. Larkin J. Long G.V. Sanborn R.E. Chiarion-Sileni V. Dréno B. Dalle S. Schadendorf D. Callahan M.K. Nyakas M. Atkinson V. Gomez-Roca C.A. Yamazaki N. Tawbi H.A. Sarkis N. Warad D. Dolfi S. Mitra P. Suryawanshi S. Grob J.J. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti–programmed death-1/programmed death ligand 1 therapy: Results from the phase I/IIa RELATIVITY-020 trial. J. Clin. Oncol. 2023 41 15 2724 2735 10.1200/JCO.22.02072 36780608
    [Google Scholar]
  14. Hamid O. Lewis K.D. Weise A.M. McKean M. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. J. Clin. Oncol. 2023 41 16 9501 10.1200/JCO.2023.41.16_suppl.9501
    [Google Scholar]
  15. Jang S. Efficacy of nivolumab and relatlimab-rmbw in patients with advanced melanoma who were previously treated with PD-1 inhibitor: Real world experience. >. J. Clinical. Oncol. 2023 41 e21533 10.1200/JCO.2023.41.16_suppl.e21533
    [Google Scholar]
  16. Lin C.C. Garralda E. Schöffski P. Hong D.S. Siu L.L. Martin M. Maur M. Hui R. Soo R.A. Chiu J. Zhang T. Ma B. Kyi C. Tan D.S.W. Cassier P.A. Sarantopoulos J. Weickhardt A. Carvajal R.D. Spratlin J. Esaki T. Rolland F. Akerley W. Deschler-Baier B. Rispoli L. Samant T.S. Chowdhury N.R. Gusenleitner D. Kwak E.L. Askoxylakis V. De Braud F. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology 2024 13 1 2290787 10.1080/2162402X.2023.2290787 38170160
    [Google Scholar]
  17. Jenkins R.W. Fisher D.E. Treatment of Advanced Melanoma in 2020 and Beyond. J. Invest. Dermatol. 2021 141 1 23 31 10.1016/j.jid.2020.03.943 32268150
    [Google Scholar]
  18. Knight A. Karapetyan L. Kirkwood J.M. Immunotherapy in melanoma: Recent advances and future directions. Cancers (Basel) 2023 15 4 1106 10.3390/cancers15041106 36831449
    [Google Scholar]
  19. Switzer B. Puzanov I. Skitzki J.J. Hamad L. Ernstoff M.S. Managing metastatic melanoma in 2022: A clinical review. JCO Oncol. Pract. 2022 18 5 335 351 10.1200/OP.21.00686 35133862
    [Google Scholar]
  20. Chocarro L. Blanco E. Arasanz H. Fernández-Rubio L. Bocanegra A. Echaide M. Garnica M. Ramos P. Fernández-Hinojal G. Vera R. Kochan G. Escors D. Clinical landscape of LAG-3-targeted therapy. Immuno-Oncology and Technology 2022 14 100079 10.1016/j.iotech.2022.100079 35755891
    [Google Scholar]
  21. Wolchok J.D. Kluger H. Callahan M.K. Postow M.A. Rizvi N.A. Lesokhin A.M. Segal N.H. Ariyan C.E. Gordon R.A. Reed K. Burke M.M. Caldwell A. Kronenberg S.A. Agunwamba B.U. Zhang X. Lowy I. Inzunza H.D. Feely W. Horak C.E. Hong Q. Korman A.J. Wigginton J.M. Gupta A. Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013 369 2 122 133 10.1056/NEJMoa1302369 23724867
    [Google Scholar]
  22. Zahm C.D. Moseman J.E. Delmastro L.E. Mcneel G. D. PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. OncoImmunology 2021 10 1 1912892 10.1080/2162402X.2021.1912892 33996265
    [Google Scholar]
  23. Zahm C.D. Colluru V.T. McIlwain S.J. Ong I.M. McNeel D.G. TLR stimulation during T-cell activation lowers PD-1 expression on CD8+ T cells. Cancer Immunol. Res. 2018 6 11 1364 1374 10.1158/2326‑6066.CIR‑18‑0243 30201735
    [Google Scholar]
  24. Grosso J.F. Kelleher C.C. Harris T.J. Maris C.H. Hipkiss E.L. De Marzo A. Anders R. Netto G. Getnet D. Bruno T.C. Goldberg M.V. Pardoll D.M. Drake C.G. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 2007 117 11 3383 3392 10.1172/JCI31184 17932562
    [Google Scholar]
  25. Goldberg M.V. Drake C.G. LAG-3 in cancer immunotherapy. Curr. Top. Microbiol. Immunol. 2010 344 269 278 10.1007/82_2010_114 21086108
    [Google Scholar]
  26. Woo S.R. Turnis M.E. Goldberg M.V. Bankoti J. Selby M. Nirschl C.J. Bettini M.L. Gravano D.M. Vogel P. Liu C.L. Tangsombatvisit S. Grosso J.F. Netto G. Smeltzer M.P. Chaux A. Utz P.J. Workman C.J. Pardoll D.M. Korman A.J. Drake C.G. Vignali D.A.A. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012 72 4 917 927 10.1158/0008‑5472.CAN‑11‑1620 22186141
    [Google Scholar]
  27. Gide T.N. Paver E.C. Yaseen Z. Maher N. Adegoke N. Menzies A.M. Pires da Silva I. Wilmott J.S. Long G.V. Scolyer R.A. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. OncoImmunology 2023 12 1 2261248 10.1080/2162402X.2023.2261248 37808404
    [Google Scholar]
  28. Hao C. Tian J. Liu H. Li F. Niu H. Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma. Medicine (Baltimore) 2017 96 26 e7325 10.1097/MD.0000000000007325 28658143
    [Google Scholar]
  29. Ascierto P.A. Bono P. Bhatia S. Melero I. Nyakas M.S. Svane I-M. Larkin J. Gomez-Roca C. Schadendorf D. Dummer R. Marabelle A. Hoeller C. Maurer M. Harbison C.T. Mitra P. Suryawanshi S. Thudium K. Muñoz Couselo E. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann. Oncol. 2017 28 v611 v612 10.1093/annonc/mdx440.011
    [Google Scholar]
  30. Tawbi H.A. Hodi S. Schadendorf D. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. J. Clin. Oncol. 2023 41 16 10.1200/JCO.2023.41.16_suppl.9502
    [Google Scholar]
  31. Amaria R.N. Postow M.A. Tetzlaff M.T. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. J. Clin. Oncol. 2021 39 15 10.1200/JCO.2021.39.15_suppl.9502
    [Google Scholar]
  32. Au L. Larkin J. Turajlic S. Relatlimab and nivolumab in the treatment of melanoma. Cell 2022 185 26 4866 4869 10.1016/j.cell.2022.12.003 36563660
    [Google Scholar]
  33. Dougan M. Luoma A.M. Dougan S.K. Wucherpfennig K.W. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021 184 6 1575 1588 10.1016/j.cell.2021.02.011 33675691
    [Google Scholar]
  34. Tawbi H.A. Forsyth P.A. Hodi F.S. Algazi A.P. Hamid O. Lao C.D. Moschos S.J. Atkins M.B. Lewis K. Postow M.A. Thomas R.P. Glaspy J. Jang S. Khushalani N.I. Pavlick A.C. Ernstoff M.S. Reardon D.A. Kudchadkar R. Tarhini A. Chung C. Ritchings C. Durani P. Askelson M. Puzanov I. Margolin K.A. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 22 12 1692 1704 10.1016/S1470‑2045(21)00545‑3 34774225
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206375121250701073343
Loading
The Safety and Efficacy of Anti-LAG-3 for Patients with Melanoma: A Systematic Review and Meta-analysis Study
Bentham Science Publishers ; https://doi.org/10.2174/0118715206375121250701073343
/content/journals/acamc/10.2174/0118715206375121250701073343
/content/journals/acamc/10.2174/0118715206375121250701073343
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: relatlimab ; immunotherapy ; Melanoma ; immune checkpoint inhibitors ; anti-LAG-3 ; nivolumab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test